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and high TRM rate has to be improved by preemptive DLI
therapy and better supportive care.Table 1
Association of Expression of Myeloid Antigens with Survival in Adult ALL
Short Survival CD13 CD33 CD13 or 33 or 117
RFS24months 44% vs 16%,
P ¼ .014
35% vs 13%,
P ¼ .044
57% vs 27%,
P ¼ .018
OS 24 months 50% vs 16%,
P ¼ .006
35% vs 16%,
P ¼ .095
64% vs 28%,
P ¼ .006
OS 60 months 34% vs 8%,
P ¼ .979
24% vs 17%,
P ¼ .591
46% vs 23%,
P ¼ .138222
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Allogeneic hematopoietic cell transplantation (HCT) is the
only curative therapy for Ph+ ALL. Reduced intensity condi-
tioning (RIC) has been explored to limit transplant related
mortality (TRM) while allowing engraftment and the graft-
versus- leukemia effect, perhaps enhanced by use of TKI and
monitoring for MRD by cytogenetic and molecular tech-
niques. Data on TKI and pre-transplant MRD on RIC HCT
outcomes are lacking.
We analyzed 197 adults with Ph+ ALL in CR1 reported to
CIBMTR between 2001-2009 and collected data on pre- and
post-HCT TKI administration and pre-transplant MRD. Sixty-
seven patients receiving RIC were matched with 130 mye-
loablative (MA) HCT recipients (matched for age, donor type
and transplant year). Median age in RIC (54 years) was older
than MA (50 years). The RIC group had more frequent pre-
HCT fungal infections and a longer time from diagnosis to CR.
Themajority in both groups received TKI pre-transplant (RIC:
76% vs MA: 78%) while only 31% (RIC) and 17% (MA) received
TKI post-transplant. Most patients had MRD monitored pre-
HCT by cytogenetic testing (89%) or BCR/ABL PCR (64%).
TRM at 1 year was almost 3-fold lower following RIC
compared to MA HCT (13% vs 36%; P < .001). In contrast, the
3-yr relapse rate was higher after RIC HCT (49% vs 28%; P ¼
.058) resulting in similar 3 year overall survival (OS) and
disease-free survival (DFS) following RIC and MA allograft
(OS: 39% vs 35%, P ¼ .62; DFS: 26% vs 28%, P ¼ .75). In
multivariate analysis, RIC was associated with 2 fold
increased relapse risk, but had no signiﬁcant impact on
survival. Post-transplant TKI use and younger age (< 40
years) associated with signiﬁcantly lower TRM and improved
OS. Probability of grade II-IV acute GVHDwas 30% and 47% in
RIC and MA groups respectively (P ¼ .014), while condi-
tioning intensity did not alter the incidence of chronic GVHD.
Pre-transplant TKI therapy might inﬂuence clearance of
MRD pre-HCT and risk of relapse. Among 153 patients who
received pre-HCT TKI, complete molecular and cytogenetic
remission was 22% (RIC) and 26% (MA); similar to pre-HCT
MRD status of patients without TKI (RIC 19%; MA 18%).
Importantly, in adjusted multivariate analysis, positive BCR/
ABL pre-HCT was strongly associated with increased relapse
(HR 2.72; P¼ .003) anduse of pre-HCTTKIwas associatedwith
a2-fold reduction in relapse (HR0.49;P¼.003).MRDpositivity
or pre-transplant TKI had no signiﬁcant inﬂuence on survival.
In this matched case-control study, we demonstrated that
RIC HCT yields similar survival of adults with Ph+ALL in CR1
compared to MA allografts. Importantly, relapse remains
higher after RIC HCT. TKI administration prior to HCT can
reduce the relapse to achieve the negative MRD status e
which is the strongest predictor of leukemia recurrence.MRD reduction pre-allograft therefore remains the impor-
tant target for future clinical trials, particularly for patients
who are candidates for RIC HCT.
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Background: Adult patients (pts) with acute lymphoblastic
leukemia (ALL) are stratiﬁed into standard- and high-risk
groups based on WBC count, karyotype and response to
induction chemotherapy. Nevertheless, the standard-risk
group (SR) is heterogeneous with 40%-50% of pts relapse, and
the survival varies from a few months to decades. The role of
immunophenotyping in further sub-stratifying the standard
risk group has not been assessed in adult pts.
Patients and Methods: Out of 161 adult ALL pts diagnosed
and treated at the L/BMT Program of BC between 1989 and
2010, 81 SR pts were separated out based on: WBC50X109/
L (B-ALL) or 100X109/L (T-ALL), absence of adverse cyto-
genetics (i.e. t(9;22), BCR-ABL fusion, complex karyotype (5
abnormalities), t(4;11), t(1;19), low hypodiploid/near trip-
loid), and complete remission (CR) following induction
chemotherapy. The immunophenotype of this group was
reviewed, reanalyzed, and correlated with CR, relapse,
relapse-free survival (RFS), and overall survival (OS). Pts were
treated with a consistent chemotherapy regimen: Induction
consisted of prednisone, vincristine and daunorubicin  L-
asparaginase. A second phase of induction comprised of
cyclophosphamide, cytarabine, methotrexate and mercap-
topurine. Intensiﬁcation was with dexamethasone, vincris-
tine, daunorubicin, cyclophosphamide, cytarabine and
thioguanine. Four cycles of consolidation with cytarabine
and tenoposide were given followed by 2-year maintenance
oral chemotherapy with methotrexate and mercaptopurine.
Results: Eighty-one standard-risk adult ALL pts (62 B-ALL, 19
T-ALL) were identiﬁed, (50 males , 31 females), median age
33 years (16-66). With a median follow up of 30 months (3-
235), 32 pts (40%) relapsed within 1-136 months. The
median OS and RFS were 30 months (3-235) and 26 months
(1-235) respectively. CD13, CD33 and CD117 data was avail-
able in 59, 58 and 50 pts respectively. They were positive in
17 (29%), 13 (22%) and 0 (0%) pts respectively. At least one of
CD13 or 33 or 117 was available in 61, and positive in 25 of
them (41%). Aberrant expression of myeloid antigens was
associated with early relapse (median 8 vs 16 months),
shorter survival (median 11 vs 28 months). OS at 24 months
and 60 months and RFS at 24 months were inferior in ALL
patients expressing myeloid antigens (Table 1).
Conclusion: In adult patients with standard-risk ALL, aber-
rant expression of myeloid antigens indicates early relapse,
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sive therapy may be considered in this subgroup.224
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The optimal timing of hematopoietic cell transplantation
(HCT) in AML is still under debate. We addressed this ques-
tion in the AML 2003 study, a large, multicenter, open-label,
randomized study of the German SAL group. All patients
received one cycle of induction therapy (IT). Upfront
molecular characterization, HLA typing and donor search
were performed. The transplant strategy was tailored to AML
risk and to donor availability. Patients aged 18-60 years were
randomly assigned upfront 1:1 to either one of two trans-
plant strategies: In the control arm HLA-identical sibling HCT
was scheduled in ﬁrst complete remission for patients with
intermediate cytogenetic risk AML and related or unrelated
compatible HCT for patients with a complex karyotype (CK).
In the experimental arm the indication for allogeneic HCT
was extended to patients with an FLT3-ITD allelic ratio >0.8
(mutant/wild type), >10% marrow blasts on day 15 after IT1
and patients with adverse karyotypes, including: -7, -5,
del(5q), inv(3q), t(3;3), t(6;9), t(6;11), t(11;19) (q23;p13.1).
Furthermore, HCT was scheduled earlier, i.e. in aplasia after
the ﬁrst or the second cycle of IT.
Between December 1st, 2003 and November 26th, 2009
1179 patients were assigned randomly either to the experi-
mental (N¼598) or the control intervention (N¼581). The
median age was 48 years (range, 18 to 60 years) and the
median observation time now is 52 months. In the intent-to-
treat analysis the hazard ratio of the treatment effect
(experimental versus control) was 0.92 (95% CI, 0.75 to 1.14;
P ¼ .45) for the primary endpoint overall survival (OS) and
0.85 (95% CI, 0.71 to 1.02; P¼ .08) for the secondary endpoint
event-free survival (EFS). However, the rate of patients who
received allogeneic HCT as ﬁrst post-remission therapy was
only 39% in the experimental arm and 20% in the control arm.
Thus, the analysis according to the intent-to-treat could not
discriminate appropriately between the two treatment
strategies. In an exploratory analysis, we therefore analyzed
the effect of allogeneic HCT as a time-dependent covariate in
a Cox-regressionmodel. We adjusted for the cytogenetic risk,age, ECOG performance status, white blood cell count, and
LDH at diagnosis. In this as-treated analysis the adjusted
hazard ratio for the treatment (allogeneic HCT versus
chemotherapy) was 0.73 (95% CI, 0.59 - 0.89; P ¼ .002) for OS
and 0.67 (95% CI, 0.55 - 0.82; P < .001) for EFS. This analysis
corrects appropriately for a classical time-selections bias.
However, a patient selection based on comorbidity or ﬁtness
cannot be ruled out.
In conclusion, a survival beneﬁt from early compared to
late allogeneic HCT could not be shown in the intent-to-treat
analysis of this large randomized trial using a risk-adapted
transplant strategy. However, the results of the as-treated
analysis suggest a substantial beneﬁt from allogeneic HCT in
ﬁrst remission versus chemotherapy.
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Mixed phenotype acute leukemia (MPAL) is a rare
leukemia with features of both myeloid and lymphoid
lineage. The 2008 World Health Organization (WHO) deﬁ-
nition of MPAL is based on the expression of strictly speciﬁc
T-lymphoid (cytoplasmic CD3) and myeloid (myeloperox-
idase) antigens, and B-cell lineage assignment relies on the
expression of CD19 together with other B celleassociated
markers (Borowitz et al. World Health Organization Classi-
ﬁcation of Tumours: Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues. 2008). In this retro-
spective review, we analyzed the clinical features and
treatment outcomes of patients treated at MDACC between
5/2004 and 6/2012 who fulﬁlled the diagnostic criteria for
MPAL. We identiﬁed a total of 41 patients with a median age
of 47 years (range 9 e 82; 63% male) with characteristics
described in the table below. Twenty one (51%) patients had
leukemia with myeloid plus B-lymphoid (M/B) markers, 18
(44%) with myeloid plus T-lymphoid (M/T) markers, and 2
(5%) with B-lymphoid plus T-lymphoid (B/T) markers. Cyto-
genetic analysis showed 31 patients (76%) had an abnormal
